Usefulness of Preheparin Lipoprotein Lipase Mass as a Parameter for Predicting the Efficacy of Colestimide
This study was conducted to clarify the characteristics of colestimide responders. Forty-seven non-diabetic patients with high levels of low-density lipoprotein cholesterol (LDL-C) received colestimide at 3,000 mg/day and were followed up for 4 months. After 4 months, body weight was reduced but the change was not statistically significant. Total serum cholesterol (TC) and LDL-C levels significantly decreased from 280 to 232 mg/dl and from 195 to 150 mg/dl, respectively (<I>p</I> < 0.01 versus before colestimide was administered). Serum triglyceride (TG) levels increased, but the change was not significant. Preheparin lipoprotein lipase mass (preheparin LPL mass) at baseline was significantly higher in colestimide responders (greater than a 20% decrease of LDL-C: <I>n</I> = 28) than non-responders (76.2 ng/ml versus 50.3 ng/ml, <I>p</I> < 0.05: <I>n</I> = 19). Next, the subjects were divided into those with a high (<I>n</I> = 33) and low (<I>n</I> = 14) preheparin LPL mass at baseline. LDL-C levels were significantly decreased in patients with a high preheparin LPL mass while TG levels were significantly increased in patients with a low preheparin LPL mass. These results suggest that baseline preheparin LPL mass may be a marker of the response to colestimide.
- Journal of atherosclerosis and thrombosis
Journal of atherosclerosis and thrombosis 12(4), 218-224, 2005-08-25
Japan Atherosclerosis Society